Tin tức & Cập nhật

In children with chronic hepatitis C (CHC), effective treatment with sofosbuvir/velpatasvir (SOF/VEL) results in improvements in certain areas of their well-being at 1 year. This suggests some patient-reported outcomes (PRO) benefits of direct-acting antiviral (DAA) therapy. However, the parents’ proxy reports show a decrease in the patients’ school functioning.

In the absence of infant hepatitis B immune globulin (HBIg), maternal tenofovir disoproxil fumarate (TDF) prophylaxis combined with infant hepatitis B virus (HBV) immunization provide sufficient protection against HBV infection in infants, findings from the iTAP-2 study suggest. However, the risk of infection was not demonstrably below 2 percent.

Following the switch from dolutegravir plus emtricitabine/tenofovir disoproxil fumarate (DTG+F/TDF), treatment with bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) has shown efficacy in keeping HIV-1 and hepatitis B virus (HBV) at low levels in the blood through 48 weeks of the open-label extension (OLE) phase of the ALLIANCE study.

Repeat transarterial chemoembolization (TACE) is not recommended for patients with hepatocellular carcinoma (HCC) who have persistent liver function deterioration after initial TACE, particularly if they have suboptimal baseline liver function or excessive tumour burden, according to researchers from the Chinese University of Hong Kong (CUHK).

Combined use of sodium-glucose cotransporter 2 inhibitors (SGLT2i) and pioglitazone may be a potentially useful strategy to ameliorate metabolic dysfunction–associated steatohepatitis (MASH) in patients with type 2 diabetes (T2D), according to a real-world study conducted by researchers from the University of Hong Kong and Queen Mary Hospital (QMH).